Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...

Are hyped ingredients falling short when you apply them on your skin? Here’s what it means when a product fails and what you can try instead.

A female fencer was disqualified from a competition for refusing to compete against a transgender opponent, USA Fencing told ABC News.